Will post-treatment controllers guide us towards an HIV cure?

Image: nevodka/Shutterstock.com

There exists a few people living with HIV who, after stopping antiretroviral therapy (ART), manage to sustain the viral load suppression – no viral rebound – achieved while on treatment, for months or even years. This is commonly described as an HIV functional cure or ART-free HIV remission.

Though rare, these individuals, termed post-treatment controllers (PTCs), are of increasing interest for HIV research, as their response to HIV treatment is quite exceptional. Scientists believe that studying this population and understanding the mechanisms behind capacity to control HIV may help them discover ways to induce a similar response to treatment in a larger population of people living with HIV.

Interest in the issue was triggered by a 1999 report of an individual who was able to control HIV without ART after several treatment interruptions, as well as the VISCONTI cohort of 14 individuals who showed control of the virus after interrupting their treatment (which, in most cases, had been initiated during primary infection).


spontaneous controllers

A small subset of people living with HIV who are able to control HIV replication in the absence of antiretroviral treatment for an unusually long period of time. Definitions vary, but an elite controller is usually defined as a person whose viral load has remained below 50 copies. However, because HIV continues to replicate even in elite controllers, ART is recommended for elite controllers who have declining CD4 counts or who develop HIV-related complications. Elite controllers and viraemic controllers are members of a larger group known as HIV controllers. Around half of HIV controllers can also be described as long-term non-progressors.


The disappearance of signs and symptoms of a disease, usually in response to treatment. The term is often used in relation to cancer, indicating that there is no evidence of disease, although the possibility of cancer remaining in the body cannot be ruled out. In HIV, remission is an alternative term for ‘functional cure’. A sustained ART-free remission would boost the immune system to induce long-term control of HIV, allowing a person living with HIV to maintain an undetectable viral load without daily medication.

Fiebig stages

A classification system used to describe the stages of early HIV infection, based on the timing and results of diagnostic tests. During the eclipse phase, no markers of HIV can be identified. This is followed by Fiebig stage I (HIV RNA can be detected in a viral load test), stage II (p24 antigen can also be detected) and stage III (HIV antibodies detectable for the first time). Stages IV, V and VI correspond with the evolution of results on the Western Blot test. The eclipse phase may last around ten days; Fiebig stage III is reached in most individuals within one month; and it may take around three months to reach stage VI.


The ‘HIV reservoir’ is a group of cells that are infected with HIV but have not produced new HIV (latent stage of infection) for many months or years. Latent HIV reservoirs are established during the earliest stage of HIV infection. Although antiretroviral therapy can reduce the level of HIV in the blood to an undetectable level, latent reservoirs of HIV continue to survive (a phenomenon called residual inflammation). Latently infected cells may be reawakened to begin actively reproducing HIV virions if antiretroviral therapy is stopped. 

immune system

The body's mechanisms for fighting infections and eradicating dysfunctional cells.

Because of the increasing need to comprehensively understand post-treatment control, earlier this year Dr Jonathan Li and colleagues from Harvard Medical School published a thorough review of the most recent findings on PTCs and discussions around unanswered questions in this field.

What is post-treatment control?

The frequency of post-treatment control varies widely in studies of individuals who discontinue ART, probably due to differences in the characteristics of the study populations, study designs and definitions of PTCs.  

At any rate, the review’s authors highlight the challenge of reaching a consensual definition of post-treatment control of HIV. Definitions differ between studies, with the duration of post-treatment virological control ranging from a six-month to a two-year period. Additionally, there are at least two ways to measure the loss of virologic control:

  • Two consecutive viral loads above 50 copies.
  • One to four consecutive viral loads higher than 400 copies.

The authors seem confident enough with the definition used in the CHAMP (Control of HIV after Antiretroviral Medication Pause) study. CHAMP is a pooled analysis of fourteen different studies that identified 67 post-treatment controllers, based on the following definition: persons who kept their viral loads below 400 copies, up to two-thirds or more of time points within a period of at least or over 24 weeks after ART interruption.

The characteristics of post-treatment controllers

In the studies included in Li’s review, the median age of the PTCs who were discovered ranged from 27 to 46 years old. Most were male, undoubtedly due to the under-recruitment of women in clinical trials. However, some studies have actually shown that women may have a better chance of achieving post-treatment control.

Most findings have come from Europe and North America, so studies of post-treatment control in other parts of the world are warranted. SPARTAC, an international clinical trial that compared treatment strategies at the time of primary infection, reported that African participants had lower viral loads prior to starting ART, and a longer duration of viral remission after ART interruption, than their non-African counterparts.

The majority of PTCs are individuals who initiated ART during early HIV infection. In the CHAMP study, 13% of early treated participants met the PTC criteria after treatment interruption, whereas 4% of those treated during chronic infection did so.

Viral dynamics matters too. In CHAMP, three different groups of PTCs were described:

  • A persistent viral load suppression.
  • An early viral load peak > 1000 copies, before a return to control (in 45%).
  • An early viral load peak > 10000 copies, before a return to control (in 33%).

"Post-treatment control is not always durable."

As for CD4 cell counts, those of PTCs are generally high at the time of treatment interruption, ranging from 720 to 1429 cells/mm3.

As explained above, the duration of virologic control after ART interruption is key to the determination of post-treatment control. The 14 PTCs in the VISCONTI study initiated ART during early HIV infection and maintained viral suppression below 400 copies/ml for at least two years after stopping treatment, while non-controllers had a median time to viral rebound of three to four weeks.

It is important to keep in mind that post-treatment control is not always durable. As a result, PTCs need regular clinical monitoring. In the CHAMP study, with its more inclusive criterion of 24 weeks (six months) of viral suppression off-treatment, the median duration of post-treatment control was slightly over two years. However, in a period of one to five years, the proportions of PTCs sustaining virologic suppression were 75, 55, 41, 30 and 22%, respectively.

Only the future will tell if these rates can be improved by experimental interventions to increase HIV-specific immune responses.  

Post-treatment controllers are not spontaneous controllers

For quite a while, it has been known that some people living with HIV can spontaneously maintain a low viral load without ever taking ART. These ‘spontaneous controllers’ (or ‘elite controllers’) gave the first hint that a drug-free HIV remission might be achievable in other people.

Overall, although they have low or undetectable viraemia, spontaneous controllers present with a virus that can replicate and also ongoing viral replication and evolution. In these individuals, there appears to be a protective effect of cytotoxic CD8 T lymphocytes (white blood cells that kill infected cells).

Spontaneous controllers also appear to be protected by certain alleles, such as HLA B*27 and HLA B*57. HLA are molecules resting on the surface of cells to allow the immune system to identify these antigens as the body’s own. They are highly polymorphic, that is, with several different alleles (gene variants), which allow for the fine-tuning of the adaptive immune system. 

In terms of HIV control level and durability, there are similarities between spontaneous controllers and PTCs. But there is evidence that both groups are distinct from each other:

  • Cytotoxic CD8 T lymphocyte responses are far weaker in PTCs than in spontaneous controllers.
  • PTCs do not seem to possess as many HLA alleles as spontaneous controllers.
  • Symptomatic acute retroviral syndrome is frequent among PTCs.
  • Before antiretroviral treatment, PTCs’ viral loads are similar to that of non-controllers, but significantly higher than those of spontaneous controllers.
  • In PTCs, early ART initiation increases the chances of reaching post-treatment control, demonstrating a specific impact of ART.

Post-treatment controllers “represent individuals who would not have been able to achieve HIV remission” without having been on ART for a period of time, the authors say.

Mechanisms and predictors

The mechanism through which PTCs sustain HIV remission is still unclear. However, two potential factors have been identified.

  • Restricted HIV reservoirs, especially within subsets of long-living cells that may contribute to PTCs’ ability to maintain HIV remission.
  • Early ART initiation, which reduces the size of the HIV reservoir and, as a result, preserves HIV-specific T-cell responses, broad CD4 responses and humoral immunity (based on antibodies against foreign antigens, which acts as ‘flags’ to trigger specific defence mechanisms against invading pathogens, cancer cells, etc.).

"How can post-treatment control be explained, other than by the restriction of the HIV reservoir?"

The paper also reviews three reported cases of early ART initiation in infants, whose immune system is not fully developed, to illustrate further its potential impact. In one of them, a child who started ART 61 days after birth has maintained viral suppression for almost nine years following ART discontinuation, while still showing detectable HIV DNA, residual viraemia, a low level of antibodies specific to HIV and a weak T-cell response. But in none of the cases were HLA B*27 and B*57 alleles found, though they are associated with spontaneous control.

A need for a better understanding of PTCs

Although PTCs may increasingly become a model to look at for the functional cure of HIV infection, many questions about them remain unanswered. For example, what is the optimal timing of early ART initiation? Or, phrased differently, at which stage of the acute HIV infection (as classified in the six ‘Fiebig stages’) is it best to start ART?

The vast majority of PTCs in VISCONTI and CHAMP initiated ART during Fiebig stages III-V (after HIV antibodies were produced). In a small study where ART was started at stage I, no PTC was identified, meaning that initiating treatment too early may not induce post-treatment control. Also, in the three paediatric cases described above, post-treatment control could be achieved with different ART initiation times, varying from 30 hours to three months after birth.

Other examples of issues that call for research:

  • PTCs do not seem to mediate HIV suppression through the same mechanisms as those found in spontaneous controllers. What are their specific mechanisms?
  • In PTCs, how can HIV control be explained, other than by the restriction of the HIV reservoir?
  • How far do differences in the distribution of infected cell types and other factors contribute to the maintenance of a ‘deeper’ state of viral latency?

Clearly, the research agenda on post-treatment control and controllers promises to be busier than it is already. As Jonathan Li and colleagues strongly suggest, achieving its objectives will greatly contribute to the search of therapeutic interventions that can lead to sustained ART-free remission. 


Etemad B, Esmaeilzadeh E & Li J. Learning From the Exceptions: HIV Remission in Post-treatment Controllers. Frontiers in Immunology, 2019 (open access).